Full identifier: http://purl.org/np/RA3-5n-wsBtW7Cs6aHHM0w45zn-KkpfyGGx8nDhJONYFU#assertion
| Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
|---|---|---|---|---|---|---|
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Elif Ozkan
|
2022-10-13T13:48:59.639Z
|
|||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
2022-10-13T13:48:59.639916
|
Elif Ozkan
|
2022-10-13T13:48:59.639Z
|
||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Avacopan is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis) in combination with standard therapy including glucocorticoids. In Europe, it is approved for the. treatment of adults with severe, active granulomatic polyang.itis (GPA/MPA) in. combination with rituximab or cyclophosphamide.
|
Elif Ozkan
|
2022-10-13T13:48:59.639Z
|